English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/107585
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline

AuthorsRafols, Ismael ; Hopkins, Michael M.; Hoekman, Jarno; Siepel, Josh; O'Hare, Alice; Perianes-Rodríguez, Antonio; Nightingale, Paul
KeywordsResearch network
Innovation
Globalisation
Pharmaceuticals
Bibliometrics
Outsourcing
Europe
Collaboration
Issue Date2012
CitationDRUID Society Conference 2012
AbstractThere is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by big pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that large pharmaceutical firms are increasingly becoming 'networks integrators' rather than the prime locus of drug discovery.
DescriptionTrabajo presentado al DRUID Society Conference on Innovation and Competitiveness - Dynamics of Organizations, Industries, Systems and Regions, celebrado en Copenhague (Dinamarca) del 19 al 21 de Junio de 2012.
Publisher version (URL)http://druid8.sit.aau.dk/druid/registrant/index/papers
URIhttp://hdl.handle.net/10261/107585
Appears in Collections:(INGENIO) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
Big Pharma.pdf1,25 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.